Showing results (11-20 of 39) with videos related to
Sort By:
Pageof 4
Journal of Virology|March 21, 2014
Within-host evolution results in antigenically distinct GII.4 norovirusesKari Debbink, Lisa C Lindesmith, Martin T Ferris, et al.Plos Pathogens|May 23, 2012
Immunogenetic mechanisms driving norovirus GII.4 antigenic variationLisa C Lindesmith, Martina Beltramello, Eric F Donaldson, et al.The Journal of Infectious Diseases|December 28, 2017
Antigenic Characterization of a Novel Recombinant GII.P16-GII.4 Sydney Norovirus Strain With Minor Sequence Variation Leading to Antibody EscapeLisa C Lindesmith, Paul D Brewer-Jensen, Michael L Mallory, et al.Plos Pathogens|February 1, 2017
Vaccination has minimal impact on the intrahost diversity of H3N2 influenza virusesKari Debbink, John T McCrone, Joshua G Petrie, et al.Journal of Virology|October 26, 2018
Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular LigandsLisa C Lindesmith, Paul D Brewer-Jensen, Michael L Mallory, et al.The Journal of Infectious Diseases|August 3, 2013
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunityKari Debbink, Lisa C Lindesmith, Eric F Donaldson, et al.The Journal of Infectious Diseases|October 4, 2017
Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody EpitopesLisa C Lindesmith, Jacob F Kocher, Eric F Donaldson, et al.Journal of Virology|May 30, 2014
Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitopeLisa C Lindesmith, Eric F Donaldson, Martina Beltramello, et al.Mbio|May 24, 2018
Bat Caliciviruses and Human Noroviruses Are Antigenically Similar and Have Overlapping Histo-Blood Group Antigen Binding ProfilesJacob F Kocher, Lisa C Lindesmith, Kari Debbink, et al.Plos Medicine|March 25, 2015
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trialLisa C Lindesmith, Martin T Ferris, Clancy W Mullan, et al.Pageof 4